---

The metabolic syndrome is a major and escalating public-health and clinical challenge worldwide in the wake of urbanization, surplus energy intake, increasing obesity, and sedentary life habits. Insulin resistance, neurohormonal activation, and chronic inflammation are the main players in the initiation, progression, and transition of metabolic syndrome to cardiovascular disease (CVD). Metabolic syndrome is associated with an increased risk of both atherosclerotic and nonatherosclerotic CVD, and confers a 5-fold increase in the risk of type 2 diabetes mellitus and 2-fold the risk of developing (CVD) over the next 5 to 10 years. A new human plasma vitamin E-binding protein afamin was reported to be highly significantly associated with criteria for metabolic syndrome in three independent human general populations. So we will focus on the role of afamin; a vitamin E binding glycoprotein as a novel marker for metabolic syndrome and related diseases

---

Mohamed, Nadia
Nadia Mohamed Ahmed, Professor of Medical Biochemistry, National Research Centre Cairo, Egypt. Member in many international societies. Member in Medical Biochemistry Unit, NRC. Reviewer in many international journals. Experience in Elisa, spectrophotometer, real time PCR and Induction of experimental diseases. Supervisor of many master and PhD

---